Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization

Inclusion criteria

• Patients who are aged ≥18 years, male or female
• Active choroidal neovascularization secondary to pathologic myopia

• high myopia (defined as spherical equivalent ≤-6.0 diopter, AL≥26mm)
• presence of posterior changes compatible with pathologic myopia
• presence of active leakage from CNV, and presence of intra-retinal or subretinal fluid or increase of central retinal thickness
• Presence of at least 1 of the following lesion types:

• subfoveal
• juxtafoveal with involvement of the central macular area
• extrafoveal with involvement of the central macular area
• margin of the optic disk with involvement of the central macular area
• 24≤BCVA≤78, at a starting distance of 4 meters using Early Treatment Diabetic Retinopathy Study (ETDRS) like VA chart ( 20/32-20/320 Snellen equivalent)
• Visual loss only due to the presence of any eligible types of CNV related to pathologic myopia, based on clinical ocular findings, fluorescein angiography (FA), and optical coherence tomography (OCT) data.
• Patients who are willing to participant in this study and sign the informed consent

Exclusion criteria

• Pan-retinal or focal/grid laser photocoagulation with involvement of the macular area in the study eye at any time
• Intraocular treatment with corticosteroids or intraocular surgery within 3 months prior to randomization and treatment with anti-VEGF or verteporfin photodynamic therapy at any time in the study eye.
• Presence of CNV secondary to any cause other than pathologic myopia.
• Presence of active infectious disease or intraocular inflammation, active or suspected periocular infection or iris neovascularization in either eye at the time of enrollment.
• Pregnant or nursing women.
• Patients with other coexisting ocular diseases, such as an abnormal cornea or a corneal infection, iridocorneal endothelial syndrome, anterior segment dysgenesis, nanophthalmos, chronic or recurrent uveitis, ocular cancer, trauma, central retinal vein occlusion, central retinal artery occlusion, and retinal detachment).
• Patients with severe systemic disease and high risk when receiving intravitreous injection of anti-VEGF, such as diabetes mellitus, hypertension, end-stage cardiac disease, nephropathy, respiratory disease, cancer and HIV.
• Patients had stroke, transient ischemic attack, myocardial infarction, acute congestive heart failure within 6 months prior to randomization